A day after completing its nearly $39 billion acquisition of Actavis Generics from Allergan, Teva signaled it wants to grow even bigger in generics through another smaller deal with Allergan, saying today it agreed to acquire its generic distribution business Anda for $500 million.
Anda distributes generic, brand, specialty, and over-the-counter pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail-order pharmacies, hospitals, clinics, and physician offices across the U.S.
Anda derives its name from the “abbreviated new drug applications” companies must submit to gain FDA approvals. As a result of the acquisition, Teva said it now holds the leading position in first-to-file opportunities with approximately 115 pending ANDAs in the U.S. and approximately 338 product registrations pending FDA approval.
Through the acquisition, Teva said, it will gain 650 employees based at Anda’s distribution centers in Olive Branch, MS; Weston, FL; and Groveport, OH.
Anda, the fourth-largest distributor of generics in the U.S., is expected to generate approximately $375 million in net revenues in the second quarter, and approximately $1.5 billion in third-party net revenue for all of 2016, Allergan said.
Teva has said it expects to achieve cost reductions or “synergies” and tax savings of approximately $1.4 billion annually by the end of 2019, by eliminating duplication and inefficiencies and creating economies of scale.
Additionally, the deal keeps growing Teva’s presence in generics just a day after the Jerusalem-based company disclosed the completion of its acquisition of Allergan’s generics unit.
Teva agreed to shell out $33.43 billion in cash and approximately 100 million Teva shares valued at $5.3 billion for Actavis Generics. The deal’s final price is slightly lower than the $40.5 billion price reported when the deal was announced last year.
“This strategic move enables us and our customers to improve capabilities and flexibility given the changes the pharmaceutical industry is currently undergoing, in order to provide access to more patients throughout the country,” Siggi Olafsson, President & CEO of Teva’s Global Generic Medicines unit, said in a statement. “The addition of Anda and their ability to service over half of their 60,000 customers within 24 hours, combined with our existing offerings, will allow us to provide even better service to our customers.”
Added Allergan CEO and President Brent Saunders: “The Anda team has played a supporting role in launching brand and generic products, such as Allergan's Vraylar™ and Liletta® and Actavis' generic Crestor®. Teva is one of Anda's most important suppliers, enhancing the significant strategic fit of Anda within Teva's business.”
Saunders said Teva’s purchase of Anda “continues our evolution as a focused branded Growth Pharma leader.”
“Growth Pharma” is Allergan’s phrase for its business model, which emphasizes category leadership across its seven therapeutic areas, customer “intimacy” or responsiveness, operational excellence, strong topline growth, and “open science R&D” or a pipeline broad enough to include 65+ mid-to-late-stage pipeline programs in development.
Teva’s acquisition of Anda is expected to close in the second half of this year, subject to antitrust clearance and satisfaction of other conditions.